Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J. Mayne, Parminder K. Judge, Doreen Zhu et al.|Nephrology Dialysis Transplantation|2024Cited by 24
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G. Herrington, Christoph Wanner, David Preiss et al.|Clinical Kidney Journal|2019Cited by 16